Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook.
According to the latest results from Gallup’s survey, self-reported obesity has started to fall, declining by nearly 3 points ...
Determined to "live as a healthy father," I administered my first injection of the lowest dose (2.5 mg) of the weight loss ...
Zacks Investment Research on MSN
DexCom Stock Falls Despite Q3 Earnings Beat, 2025 Revenue View Raised
DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus ...
Crinetics Pharmaceuticals' stock has surged after FDA approval of Palsonify for acromegaly. Click here to read the latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback